本帖最后由 老马 于 2012-1-13 21:20 编辑
0 j9 S9 a% l5 _+ {5 s7 q
# ]" e, y' b7 Q& r4 M' A8 Q) ~爱必妥和阿瓦斯丁的比较
1 e2 K1 D2 D5 K" `5 E H B6 u
: O1 D, N1 C; ? I. w2 y# g* t
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/: w2 g! y9 ` G6 U1 C" T! l
6 f: b6 @1 q, d$ W4 r
9 T l& Z, D& g$ B q
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/. x* M+ E$ n* h+ v
==================================================
9 C: E0 \- i& uOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL), p1 c& B u% Q1 }4 Q. n
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.- o& i, E5 L$ O' ^& j
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
! i& e% _$ f+ Q
|